ArticleCureus2025
Silent Metastatic Pheochromocytoma: Clinical, Diagnostic, and Management Challenges in a Resource-Limited Setting.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pheochromocytomas are rare neuroendocrine tumors arising from adrenal chromaffin cells, typically characterized by excess catecholamine secretion, which causes symptoms such as hypertension and palpitations. However, some pheochromocytomas and paragangliomas are non-functional and biochemically silent, complicating their diagnosis. Metastatic pheochromocytoma is uncommon and challenging to manage, especially in resource-limited settings. We present the case of a 50-year-old man with progressive back pain, weight loss, weakness, and intermittent sweating. Imaging revealed bilateral adrenal masses with extensive lymphadenopathy and probable hypopharyngeal metastasis. Surprisingly, plasma and urinary metanephrines were normal. A biopsy of a cervical lymph node confirmed metastatic pheochromocytoma, demonstrating chromogranin and GATA3 positivity and a Ki-67 index of 20%. Despite multidisciplinary input, the patient's lack of health insurance delayed treatment and resulted in death within one month. This case highlights the diagnostic challenges of metastatic pheochromocytoma presenting with atypical symptoms and normal catecholamine levels. It emphasizes the need for comprehensive evaluation beyond biochemical tests, including imaging and histopathology. Additionally, it illustrates how socioeconomic barriers can limit access to timely care, adversely affecting outcomes. Awareness and early multidisciplinary management are essential to improving prognosis in metastatic pheochromocytoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.